Gliadel wafer data

Of 32 patients who had surgical removal of a primary tumor, 63 percent of the 16 patients who had the carmustine-bearing wafer placed in the surgical site were still alive after a year, compared to 19 percent of 16 placebo recipients.

Both active wafer and placebo were followed by traditional radiation therapy. After two years, 5 Gliadel recipients were alive, compared to one placebo-treated patient. ...